Welcome to the world of immunohistochemistry!
📞 800-8581156 📧 info@naim.com.cn
Menu
  • Home
  • Product
  • Service and Support
    • Immunohistochemistry and Pathology
    • Immunohistochemistry Technology Exchange
    • Recommended List and Introduction of Newly Developed IHC
    • Public laboratory
    • Consultation and Feedback
  • News and Information
    • Hotspot Focus
    • Industry News
    • Maxxin Dynamics
    • Meeting Notice
  • Entering Maixin
    • Corporate Culture
    • Maisin Honors
    • Maixin Company Profile
    • Myriad Pathology Foundation Overview
  • Contact us
Close
分类
  • Consultation and Feedback
  • Hotspot Focus
  • Immunohistochemistry and Pathology
  • Immunohistochemistry Technology Exchange
  • Industry News
  • Maxxin Dynamics
  • Meeting Notice
  • News and Information
  • Public laboratory
  • Recommended List and Introduction of Newly Developed IHC
  • Service and Support
  • Uncategorized
Product Search
06 2 月

The Blossoming of Immunocytochemical Double Staining

Continue reading
06 2 月

Immunohistochemical Antibody Selection Scheme for Spleen Diseases (Part 1)

Continue reading
06 2 月

Seize the Moment, Collaborate on Research—Suggestions for Advancing COVID-19 Studies

Continue reading
06 2 月

Yongtai County Hospital Introduces Maixin Pathology Remote Frozen Diagnosis Service to Facilitate Clinical Surgeries and Promote the Implementation of Tiered Medical Care

Continue reading
06 2 月

Pathology Weekly Reading Notes by “Mai Mai” | Issue 1

Continue reading
06 2 月

The 19th Issue of “Mai Mai” Pathology Weekly Reading Notes | Immunohistochemical Markers for Diagnosis of Prostate and Seminal Vesicle Tumors

Continue reading
06 2 月

Premium Launch: Maxin EBER In Situ Hybridization Kit, Making EBV Detection Unmistakable

Continue reading
06 2 月

2019 National Pathology Technology Conference Concludes Successfully – “Immunohistochemistry Training, Maixin Achieves Outstanding Results”

Continue reading
06 2 月

Superior Choice for GIST Diagnosis: DOG1 Antibody Maixin Clone “MX067”

Continue reading
06 2 月

Ki-67: Prospects, Potential, and Challenges in Breast Cancer (Part 2)

Continue reading
  • «
  • ‹
  • 19
  • 20
  • 21
  • 22
  • 23
  • ›
  • »

Copyright © 1993 - 2017 Fuzhou Maixin Biotechnology Development Co., Ltd. MinICP No. 05015562-1 | (Fujian) - Non-commercial - 2017-0010

  • Home
  • Product
  • Service and Support
    • Immunohistochemistry and Pathology
    • Immunohistochemistry Technology Exchange
    • Recommended List and Introduction of Newly Developed IHC
    • Public laboratory
    • Consultation and Feedback
  • News and Information
    • Hotspot Focus
    • Industry News
    • Maxxin Dynamics
    • Meeting Notice
  • Entering Maixin
    • Corporate Culture
    • Maisin Honors
    • Maixin Company Profile
    • Myriad Pathology Foundation Overview
  • Contact us
Sidebar